Actinium Pharmaceuticals Inc (ATNM) Stock Analysis

Actinium Pharmaceuticals Inc (ATNM) is a publicly traded company in the HEALTHCARE sector. It trades at $1.18, carries a market capitalization of $37.02M. This page summarizes the public market data, fundamentals, and frequently asked questions for ATNM, with GNG Research's proprietary safety, quality, and valuation analysis available to members.

Sector: HEALTHCARE - BIOTECHNOLOGY

Exchange: NYSE MKT

Key Metrics

Market Sentiment

Actinium Pharmaceuticals Inc currently has a Bullish sentiment score of 0.17.

About Actinium Pharmaceuticals Inc

Actinium Pharmaceuticals, Inc. is a leading clinical-stage biopharmaceutical firm focused on developing cutting-edge therapies for bone marrow transplantation and adoptive cell therapies, with a primary emphasis on hematologic malignancies. Based in New York, the company is advancing its proprietary antibody-radionuclide conjugate platform, aimed at improving patient outcomes in both transplantation and cancer care. With a promising pipeline of therapeutic candidates and strategic collaborati...

GNG Research Analysis

GNG Research scores Actinium Pharmaceuticals Inc (ATNM) on three proprietary dimensions — a Safety score, a Quality score, and a Valuation score — alongside fair value estimates and buy-price targets for 5,000+ companies. These ratings are reserved for members. Read how the scores are calculated on our methodology page, or see GNG Research plans to unlock the full rating for ATNM.

Frequently Asked Questions

Does ATNM pay dividends?

Actinium Pharmaceuticals Inc (ATNM) does not currently pay a regular dividend.

What is ATNM's market cap?

Actinium Pharmaceuticals Inc (ATNM) has a market capitalization of $37.02M with a current stock price of $1.18.